We are live on ! Find out more
AKCA

Akcea Therapeutics Inc
AKCA

Delisted

AKCA was delisted on the 9th of October, 2020.

68 hedge funds and large institutions have $554M invested in Akcea Therapeutics Inc in 2019 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 23 increasing their positions, 19 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

21% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 19

8% less funds holding

Funds holding: 7468 (-6)

16% less call options, than puts

Call options by funds: $7.67M | Put options by funds: $9.18M

17% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 18

17% less capital invested

Capital invested by funds: $665M → $554M (-$111M)

Holders
68
Holders Change
-6
Holders Change %
-8.11%
% of All Funds
1.48%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
15
Increased
23
Reduced
19
Closed
18
Calls
$7.67M
Puts
$9.18M
Net Calls
-$1.51M
Net Calls Change
-$5.68M

AKCA Hedge Fund Activity: Q2 2019 in Review

68 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Akcea Therapeutics Inc (AKCA) for Q2 2019, worth a combined $554M — down 17% from $665M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of AKCA and 15 opened new positions — a net loss of 3 holders — while 19 trimmed existing stakes and 23 added.

The largest buyer was Bellevue Group, adding an estimated $64.1M. The largest seller was Fidelity Investments, cutting an estimated $20.1M.

  • 68 institutional investors held Akcea Therapeutics Inc (AKCA) as of Q2 2019, down from 74 in Q1 2019.
  • Funds reported $554M of Akcea Therapeutics Inc stock for Q2 2019, down 17% quarter-over-quarter.
  • 15 funds opened new Akcea Therapeutics Inc positions in Q2 2019 and 18 closed out, a net change of -3 holders.
  • The largest Akcea Therapeutics Inc buyer in Q2 2019 was Bellevue Group, an estimated $64.1M added.
  • The largest Akcea Therapeutics Inc seller in Q2 2019 was Fidelity Investments, an estimated $20.1M sold.

Based on aggregated 13F filings for Q2 2019.